secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2022-03-25T23:59:59+00:00
Accession:  0001193125-22-085244
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO settles Penn sublicense fees with $8M payment and $12M over 4 years; future fees removed
--------------------------------------------------------------------------------

- Company pays $8.0M to Penn for sublicense fees related to AbbVie collaboration agreement.
- Company will pay $12.0M over four years ($3M annually) to satisfy past/future sublicense obligations.
- Letter agreement deletes Section 3.5 of Penn-REGENXBIO License, removing obligation to pay future sublicense fees.
- Penn gains right to conduct gene therapy research outside a single identified field, with no restriction.
- Parties agree to explore further expansion of relationship, including new collaboration and alliance opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000119312522085244/0001193125-22-085244-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000119312522085244/d330891d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-085244

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer